US › Healthcare

Nephros Inc (NEPH)

US · Healthcare · Medical Instruments & Supplies

$4.23-1.63%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$6.0M

Revenue YoY

+36.2%

Net profit

$1.2M

Profit YoY

+405.1%

EPS

$0.06

EPS estimate

$0.01

Net margin

19.9%

EPS came in at 0.06 against a street estimate of 0.01 — a beat of 500.0%.

Key statistics

Market cap

$48.5M

P/E

27.9

Forward P/E

0.0

P/B

4.12

Book value

$1.10

EPS (TTM)

$0.16

52-week high

$6.42

52-week low

$2.66

50-day MA

$3.93

200-day MA

$3.90

Beta

1.56

Analyst view

Analysts rate Nephros Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.25.

Shareholding

Insiders

12.89%

Institutions

48.93%

Largest institutional holders

Fund	Stake
Wexford Capital LP	33.15%
Topline Capital Management LLC	4.93%
Vanguard Capital Management, LLC	1.83%
Petersen Flynn & Dinsmore Inc	1.19%
Bard Associates Inc	1.09%
Morgan Stanley - Brokerage Accounts	1.02%
Renaissance Technologies Corp	0.92%
Geode Capital Management, LLC	0.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nephros Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.